Country Reports

Thanks to a more stable macroeconomic and political footing than at any time in the past 15 years, Greeks once more have cause for cautious optimism about their country’s direction of travel. Many of the half a million educated young people who left the country in search of opportunities elsewhere during the crisis are returning,…

This exclusive new report, bringing together stakeholders from across the Latin American healthcare and life sciences ecosystem, shines a light on a continent, and an industry, poised for increased global relevance in the coming years. While economic and political uncertainty remain facts of life in LatAm, the region also has all the fundamentals of a…

Currently in the midst of a generational transformation of its healthcare system, Egypt has more to recommend it than ever to the global life sciences investment community. Not only is the country attempting to bring its entire 100+ million population under some form of universal health coverage for the first time, but the Egyptian leadership…

At a crucial moment ahead of a snap general election on 25 September 2022, this new report looks back at the progress that Italy’s healthcare and life sciences sector has made in recent years and assesses its future prospects. While the country’s political winds are difficult to predict, Italy’s place at the top table of…

Having foregrounded its life sciences credentials with the establishment of manufacturing and clinical trials hubs, Spain is hoping to secure its position as a globally relevant industry player. The Iberian nation can boast an advanced healthcare system – which has contributed to a life expectancy rate of around 82.4 years – one of the highest…

Saudi Arabia – by many measures the cultural, social, and economic centre of the Arab and Islamic worlds – is currently undergoing a once-in-a-lifetime transformation. The ‘Vision 2030’ transformation plan is not only reshaping the Saudi economy and reducing its dependence on petroleum revenues but is also unleashing sweeping societal changes and creating a wealth of new opportunities for savvy international investors.

Despite its diminutive size, Denmark boasts a world-renowned healthcare and life science industry containing both household pharma giants as well as a robust network of academia, a host of niche service providers, and a growing throng of biotech start-ups. With life science exports topping EUR 20 billion and growing, Denmark looks set to retain its…

On the verge of its 100th anniversary, the Republic of Turkey appears to be approaching a decisive moment in the trajectory of its healthcare industry. With a comprehensive social security system covering over 95 percent of the population already in the bag, and after more than a decade of investment on world-class infrastructure, the country…

With outstanding fundamentals, including top-class universities and hospitals, a government cognizant of the benefits that a robust research-based biopharma industry brings, and straightforward business processes, Singapore has long been a hub for life science companies looking to penetrate the vast Asia-Pacific region. This exclusive new report deep dives into Singapore’s key attractions for international investors,…

Switzerland continues to hold its own as a focal point for innovation and discovery in global medical science and ranks very highly on the radar of both Big Pharma and the international biotech community alike. As well as Switzerland’s continuing relevance to the European and global pharma industry, pharma is truly at the core of…

Become a PharmaBoardroom Member for free to access this contentJoin the 35,000+ pharmaceutical professionals who already subscribe to PharmaBoardroomRegisterAlready a member? Sign In Log into your account Email Address Password Remember Me Forgot your password? Don't have a PharmaBoardroom account? Create one

A bastion of equality with high levels of healthcare spending, excellent research and universities, a global commitment to improving health outcomes, and a deeply entrenched digital footprint, Norway is full of potential as a life sciences investment destination. This potential, however, has largely remained untapped until now, as the country has focused on its more…